An HIV Vaccine: The World's best long-term hope for ending AIDS.

Who We Are

We are the world’s largest publicly-funded international collaboration focused on the development of vaccines to prevent HIV/AIDS. Learn more >

What We Do

Our sites conduct all phases of clinical trials - from evaluating experimental vaccines for safety and immunogenicity to testing vaccine efficacy. Learn more >

Get Involved

Worldwide, thousands of people have participated in HIV vaccine trials.  Volunteers are the heroes of vaccine development. Learn more >


EXPERIMENTAL PHASE 2B HIV VACCINE REGIMEN PROVIDES INSUFFICIENT PROTECTION IN PREVENTING HIV

No safety signals of concern for study participants

SEATTLE – (Aug. 31, 2021) – A primary analysis of an experimental HIV vaccine regimen being studied in a high-incidence population of young women in sub-Saharan Africa found the experimental vaccine did not provide sufficient protection against HIV infection. No significant safety concerns were identified, but because the vaccine regimen failed to meet the study’s primary endpoint, with results falling short of statistical significance, the Imbokodo study, also called HVTN 705/HPX2008, will be discontinued.

Read Story >


Design by Cody Shipman

Volume 21, Issue 1: The Latest Issue of Community Compass

The Community Compass aims to keep the HVTN community informed about the Network’s research, sites' activities, and advances in the field of HIV Prevention and Vaccination. Read the latest issue >


Michele Andrasik, PhD

Study Participants Feel Good When Helping Others, HVTN Analysis Shows

A NIAID-funded HIV Vaccine Trials Network (HVTN) cross-protocol analysis designed to assess the self-reported beneficial and negative social impacts (NSI) experienced by study participants was published earlier this year in the Journal of Acquired Immune Deficiency Syndromes (JAIDS). The study enrolled 8347 people across 48 completed preventive HIV vaccine trials, which were conducted between December 2000 and September 2017.

Read Story >


Scholar Awards

We support the next generation of HIV researchers with structured mentoring, projects, training, and networking opportunities. Learn more >


Getting the Right Test for HIV

Getting the right test will prevent an incorrect diagnosis of HIV.  Your study site or VISP Testing Service can provide the right test.  Visit our frequently asked questions for more information.


Formation of the COVID-19 Prevention Network (CoVPN) and official website launch

CoVPN Logo
  • The COVID-19 Prevention Network (CoVPN) was formed by the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health to respond to the global pandemic. Using the infectious disease expertise of their existing research networks and global partners, NIAID has directed the networks to address the pressing need for vaccines and monoclonal antibodies (mAbs) against SARS-CoV-2. The HVTN is one of four NIAID-funded networks that constitute the CoVPN.
  • Access the official website: https://coronaviruspreventionnetwork.org  
  • Read more about the CoVPN’s observational studies currently underway:

TWITTER FEED


LATEST NEWS

HIV Vaccine Trials Network

Fred Hutchinson Cancer Research Center